ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Take aways for earnings release.

INZIRQO and TEZRULY are still in their back pocket. Though are available through many major pharmacies. Obviously are cautious not to ask about the drugs. Pretty easy to beat estimates when info is held back.

ANIP's GAAP EPS would have been $1.47 had they not bought out the royalties for $17.25 million cash.

From a epidemiological perspective, the addressable market for ACTH therapy between $8.2 B to $10.B.